Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Keros Therapeutics, Inc.KROS · Entity 6242 | CHIEF MEDICAL OFFICER | February 13, 2024 | February 15, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Keros Therapeutics, Inc.
Report date February 13, 2024 · Filed February 15, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.18 · Expires 2034-02-12 | Direct | 40,000 |
Reported balance
After 2024-02-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-13 · Grant · Acquired 40,000 · Balance 40,000 F1: 25% of the shares subject to the option shall vest on February 13, 2025, and 6.25% of the shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the option shall vest on February 13, 2025, and 6.25% of the shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Morphic Holding, Inc.
Report date August 16, 2024 · Filed August 20, 2024
Section 16 reporting ended · disclosed 2024-08-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.46 · Expires 2034-03-18 | Direct | 0 |
Reported balance
After 2024-08-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-08-16 · Disposition to issuer · Disposed 170,000 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F4: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3: The Company Stock Option ("Option") vests as to 25% of the total shares on March 18, 2025, and then 2.0833% of the remaining shares shall vest monthly thereafter, subject to the reporting person's provision of service to the issuer on each vesting date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-08-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-08-16 · Disposition to issuer · Disposed 14,000 · Balance 0 F5: Each Company Restricted Stock Unit ("RSUs") represents a contingent right to receive one (1) share of Common Stock upon settlement for no consideration. F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F7: Pursuant to the Merger Agreement, each RSU that was outstanding but not vested as of immediately prior to the Closing (the "Unvested RSU"), became immediately vested in full (the "Vested RSU"). Each Vested RSU was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the Offer Price by (ii) the number of shares of Common Stock underlying such RSU. F6: The RSUs vest as to 25% of the total shares on each of March 18, 2025, March 18, 2026. March 18, 2027 and March 18, 2028, subject to the reporting person's provision of service to the issuer on each vesting date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-08-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-08-16 · Disposition to issuer · Disposed 7,000 · Balance 0 F5: Each Company Restricted Stock Unit ("RSUs") represents a contingent right to receive one (1) share of Common Stock upon settlement for no consideration. F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F7: Pursuant to the Merger Agreement, each RSU that was outstanding but not vested as of immediately prior to the Closing (the "Unvested RSU"), became immediately vested in full (the "Vested RSU"). Each Vested RSU was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the Offer Price by (ii) the number of shares of Common Stock underlying such RSU. F8: The RSUs vest as to 50% of the total shares on March 18, 2025 and 50% of the total shares on September, 2025, subject to the reporting person's provision of service to the issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.
F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding.
F3: The Company Stock Option ("Option") vests as to 25% of the total shares on March 18, 2025, and then 2.0833% of the remaining shares shall vest monthly thereafter, subject to the reporting person's provision of service to the issuer on each vesting date.
F4: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof.
F5: Each Company Restricted Stock Unit ("RSUs") represents a contingent right to receive one (1) share of Common Stock upon settlement for no consideration.
F6: The RSUs vest as to 25% of the total shares on each of March 18, 2025, March 18, 2026. March 18, 2027 and March 18, 2028, subject to the reporting person's provision of service to the issuer on each vesting date.
F7: Pursuant to the Merger Agreement, each RSU that was outstanding but not vested as of immediately prior to the Closing (the "Unvested RSU"), became immediately vested in full (the "Vested RSU"). Each Vested RSU was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the Offer Price by (ii) the number of shares of Common Stock underlying such RSU.
F8: The RSUs vest as to 50% of the total shares on March 18, 2025 and 50% of the total shares on September, 2025, subject to the reporting person's provision of service to the issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 16, 2024 Filed Aug 20, 2024 19:02 UTC | Morphic Holding, Inc. MORF · Entity 88114 | Disposition to issuerRestricted Stock Unit · Derivative | 7,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-021752 · form4-08202024_110854.xml · derivative · entry 3 Cooper Simon Peter · CIK 0001877225 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires not disclosed F5 · derivative.exercise_price: Each Company Restricted Stock Unit ("RSUs") represents a contingent right to receive one (1) share of Common Stock upon settlement for no consideration. F1 · kind: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2 · kind: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F7 · price: Pursuant to the Merger Agreement, each RSU that was outstanding but not vested as of immediately prior to the Closing (the "Unvested RSU"), became immediately vested in full (the "Vested RSU"). Each Vested RSU was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the Offer Price by (ii) the number of shares of Common Stock underlying such RSU. F8 · derivative.exercise_date: The RSUs vest as to 50% of the total shares on March 18, 2025 and 50% of the total shares on September, 2025, subject to the reporting person's provision of service to the issuer on each vesting date. F8 · derivative.expiration_date: The RSUs vest as to 50% of the total shares on March 18, 2025 and 50% of the total shares on September, 2025, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 19:02 UTC | Morphic Holding, Inc. MORF · Entity 88114 | Disposition to issuerRestricted Stock Unit · Derivative | 14,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-021752 · form4-08202024_110854.xml · derivative · entry 2 Cooper Simon Peter · CIK 0001877225 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,000 shares Expires not disclosed F5 · derivative.exercise_price: Each Company Restricted Stock Unit ("RSUs") represents a contingent right to receive one (1) share of Common Stock upon settlement for no consideration. F1 · kind: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2 · kind: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F7 · price: Pursuant to the Merger Agreement, each RSU that was outstanding but not vested as of immediately prior to the Closing (the "Unvested RSU"), became immediately vested in full (the "Vested RSU"). Each Vested RSU was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the Offer Price by (ii) the number of shares of Common Stock underlying such RSU. F6 · derivative.exercise_date: The RSUs vest as to 25% of the total shares on each of March 18, 2025, March 18, 2026. March 18, 2027 and March 18, 2028, subject to the reporting person's provision of service to the issuer on each vesting date. F6 · derivative.expiration_date: The RSUs vest as to 25% of the total shares on each of March 18, 2025, March 18, 2026. March 18, 2027 and March 18, 2028, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 19:02 UTC | Morphic Holding, Inc. MORF · Entity 88114 | Disposition to issuerStock Option (Right to Buy) · Derivative | 170,000 | Not disclosed Strike: $33.46 | Not disclosed |
DisclosureSEC source: 0001415889-24-021752 · form4-08202024_110854.xml · derivative · entry 1 Cooper Simon Peter · CIK 0001877225 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 170,000 shares Expires 2034-03-18 F1 · kind: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2 · kind: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F4 · price: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3 · derivative.exercise_date: The Company Stock Option ("Option") vests as to 25% of the total shares on March 18, 2025, and then 2.0833% of the remaining shares shall vest monthly thereafter, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| March 18, 2024 Filed Mar 19, 2024 19:07 UTC | Morphic Holding, Inc. MORF · Entity 88114 | GrantRestricted Stock Unit · Derivative | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008643 · form4-03192024_110335.xml · derivative · entry 3 Cooper Simon Peter · CIK 0001877225 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The RSUs vest as to 50% of the total shares on March 18, 2025 and 50% of the total shares on September 18, 2025, subject to the reporting person's provision of service to the issuer on each vesting date. F4 · derivative.expiration_date: The RSUs vest as to 50% of the total shares on March 18, 2025 and 50% of the total shares on September 18, 2025, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| March 18, 2024 Filed Mar 19, 2024 19:07 UTC | Morphic Holding, Inc. MORF · Entity 88114 | GrantRestricted Stock Unit · Derivative | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008643 · form4-03192024_110335.xml · derivative · entry 2 Cooper Simon Peter · CIK 0001877225 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 25% of the total shares on each of March 18, 2025, March 18, 2026, March 18, 2027 and March 18, 2028, subject to the reporting person's provision of service to the issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vest as to 25% of the total shares on each of March 18, 2025, March 18, 2026, March 18, 2027 and March 18, 2028, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| March 18, 2024 Filed Mar 19, 2024 19:07 UTC | Morphic Holding, Inc. MORF · Entity 88114 | GrantEmployee Stock Options (right to buy) · Derivative | 170,000 | $0.00 Strike: $33.46 | $0.00 |
DisclosureSEC source: 0001415889-24-008643 · form4-03192024_110335.xml · derivative · entry 1 Cooper Simon Peter · CIK 0001877225 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires not disclosed F1 · derivative.exercise_date: The option vests as to 25% of the total shares on March 18, 2025, and then 2.0833% of the remaining shares shall vest monthly thereafter, subject to the reporting person's provision of service to the issuer on each vesting date. F1 · derivative.expiration_date: The option vests as to 25% of the total shares on March 18, 2025, and then 2.0833% of the remaining shares shall vest monthly thereafter, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 20:37 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantEmployee Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $56.18 | $0.00 |
DisclosureSEC source: 0001415889-24-003999 · form4-02162024_010205.xml · derivative · entry 1 Cooper Simon Peter · CIK 0001877225 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2034-02-12 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 13, 2025, and 6.25% of the shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 16:15 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantEmployee Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $54.38 | $0.00 |
DisclosureSEC source: 0001209191-23-010561 · doc4.xml · derivative · entry 1 Cooper Simon Peter · CIK 0001877225 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-02-15 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on February 16, 2024, and 6.25% of the shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| January 21, 2022 Filed Jan 25, 2022 16:12 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $46.30 | $0.00 |
DisclosureSEC source: 0001209191-22-004758 · doc4.xml · derivative · entry 1 Cooper Simon Peter · CIK 0001877225 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-01-20 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on January 19, 2023, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 16:56 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | GrantEmployee Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $34.98 | $0.00 |
DisclosureSEC source: 0001209191-21-050890 · doc4.xml · derivative · entry 1 Cooper Simon Peter · CIK 0001877225 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-08-09 F1 · derivative.exercise_date: The shares subject to the option shall vest twenty-five percent (25%) on August 2, 2022, and six and one-quarter percent (6.25%) of such shares shall vest at the end of each successive three (3) month period thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.